Published in Nat Biotechnol on April 01, 2007
NCI Image-Guided Drug Delivery Summit. Cancer Res (2011) 0.83
Targeting and imaging signature caveolar molecules in lungs. Proc Am Thorac Soc (2009) 0.81
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell (2006) 3.10
The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell (2009) 3.08
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 2.83
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell (2010) 2.64
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest (2012) 2.58
Role of VEGF-A in vascularization of pancreatic islets. Curr Biol (2003) 2.56
VEGFA is necessary for chondrocyte survival during bone development. Development (2004) 2.54
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood (2012) 2.43
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol (2005) 2.38
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol (2003) 2.24
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol (2006) 2.10
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res (2008) 2.08
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
A direct and melanopsin-dependent fetal light response regulates mouse eye development. Nature (2013) 1.98
Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development (2005) 1.93
Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature (2011) 1.91
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest (2012) 1.90
Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell (2012) 1.79
The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A (2003) 1.78
VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res (2008) 1.76
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A (2004) 1.75
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73
Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell (2009) 1.72
Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation (2004) 1.71
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol (2010) 1.70
Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol (2005) 1.64
Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology (2012) 1.63
Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci (2008) 1.63
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood (2004) 1.62
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci (2009) 1.58
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost (2004) 1.55
The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl) (2002) 1.54
Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol (2007) 1.51
Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol (2008) 1.51
Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. Cell Res (2013) 1.46
Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta. Development (2005) 1.44
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol (2012) 1.30
Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res (2006) 1.29
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol (2006) 1.29
Antiangiogenic therapy for cancer: an update. Cancer J (2007) 1.27
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A (2011) 1.26
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A (2013) 1.25
Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat (2008) 1.23
Endothelium-microenvironment interactions in the developing embryo and in the adult. Dev Cell (2007) 1.22
Characterization and regulation of bv8 in human blood cells. Clin Cancer Res (2009) 1.21
Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J Biol Chem (2001) 1.20
Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest Ophthalmol Vis Sci (2008) 1.19
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol (2002) 1.16
Radial construction of an arterial wall. Dev Cell (2012) 1.16
The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf. Development (2009) 1.16
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol (2012) 1.15
Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med (2002) 1.14
The heart endocardium is derived from vascular endothelial progenitors. Development (2011) 1.13
Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech (2010) 1.13
Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PLoS One (2010) 1.11
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol (2012) 1.11
A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res (2010) 1.10
Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A (2007) 1.10
Vascular endothelial growth factor co-ordinates proper development of lung epithelium and vasculature. Mech Dev (2005) 1.10
S1P1 inhibits sprouting angiogenesis during vascular development. Development (2012) 1.08
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife (2013) 1.06
Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun (2011) 1.03
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy. EMBO Mol Med (2013) 1.00
VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. Am J Physiol Regul Integr Comp Physiol (2002) 0.99
Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. Am J Pathol (2010) 0.98
Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J Biol Chem (2012) 0.98
Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest (2007) 0.98
Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res (2008) 0.97
Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate (2004) 0.92
EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. Trends Cardiovasc Med (2003) 0.91
Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Sci Signal (2013) 0.91